Poland· PL-100375330
Zavicefta
A ceftazidim und beta-lactamase-inhibitor product containing ceftazidimum + avibactamum, registered in Poland by Pfizer Ireland Pharmaceuticals. The same ATC class is registered in 10 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Ceftazidim und beta-lactamase-inhibitor is registered in 10 of 19 countries.
Countries holding a registration under ATC J01DD52 (ceftazidim und beta-lactamase-inhibitor), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Ceftazidim und beta-lactamase-inhibitor · ATC J01DD52
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of ceftazidim und beta-lactamase-inhibitor costs, country by country.
Normalised to the WHO defined daily dose (6 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ceftazidim und beta-lactamase-inhibitor · price per daily dose (6 g)
USD · FX 28 Sept 2026
- CH Switzerland$407.92
The record
At a glance
URPL (Poland)- Active substance
- Ceftazidimum + Avibactamum
- Manufacturer
- Pfizer Ireland Pharmaceuticals
- Country
- Poland (PL)
- ATC code
- J01DD52
- ATC class
- Ceftazidim und Beta-Lactamase-Inhibitor
- Defined daily dose
- 6 g, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05415062308530
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ceftazidim und beta-lactamase-inhibitor in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaZAVICEFTAPfizer Ireland Pharmaceuticals Unlimited Company, Ringaskiddy
- FinlandZaviceftaPfizer Ireland Pharmaceuticals Unlimited Company
- SpainZAVICEFTA 2 G/0,5 G POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONPfizer Ireland Pharmaceuticals Unlimited Company
- United StatesAVYCAZAllergan, Inc.
- United KingdomZavicefta 2g/0.5g powder for concentrate for solution for infusion vialsPfizer Ltd
- SwitzerlandZavicefta, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungPfizer AG
- IcelandZaviceftaPfizer Ireland Pharmaceuticals
- NetherlandsZAVICEFTA 2 g/0,5 g, poeder voor concentraat voor oplossing voor infusiePfizer Ireland Pharmaceuticals, Operations Services Group
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zavicefta
- Liechtenstein · Zavicefta
- Norway · Zavicefta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/864e17b5-2935-4eea-b1bf-e8bc0e1f3ba6 GET /v1/drugs/864e17b5-2935-4eea-b1bf-e8bc0e1f3ba6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do sporządzania koncentratu roztworu do infuzji",
"source": "urpl",
"strength": "2 g + 0,5 g",
"packaging": "05415062308530 ¦ Rpz ¦ EU/1/16/1109/001 ¦ 117111\n10 fiol.",
"substance": "Ceftazidimum 2 g + Avibactamum 0.5 g",
"common_name": "Ceftazidimum + Avibactamum",
"pl_product_id": "100375330",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about ceftazidim und beta-lactamase-inhibitor.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.